TY  - JOUR
AU  - Tadić, Marin
AU  - Lazović, Jelena
AU  - Panjan, Matjaž
AU  - Kralj, Slavko
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10189
AB  - Controlled spatial arrangements of superparamagnetic iron oxide nanoparticles (SPIONs) in complex nanostructures determine fine tuning of physico-chemical properties which, in turn, may lead to new practical applications. We report here on newly observed properties of hierarchical SPIONs nanostructure with bundle-like morphology, also known as nanobundles. Colloidal chemical processes and sol-gel synthesis were used for the synthesis of nanobundles, i.e. i) self-assembly of SPIONs into magnetic nanoparticle clusters, ii) their magnetic assembly to the nanochains, and finally iii) formation of bundle-like hierarchical nanostructure. An XRPD measurements show spinel crystal structure of maghemite/magnetite nanoparticles, EDS analysis reveals Fe, Si and O as main elements whereas SEM/TEM analysis show silica-coated magnetic nanoclusters (∼100 nm) and their hierarchical assemblies with bundle-like morphology of ∼8 μm length and ∼1 μm width. TEM analysis revealed core-shell nature of iron oxide nanoparticle clusters with their size of around 80 nm that were coated by an amorphous silica shell with thickness of ∼15 nm. The nanoclusters in the core are constructed of maghemite/magnetite nanoparticle assembly with primary iron oxide nanoparticle size about 10 nm. The magnetization M data as a function of an applied external magnetic field H were successfully fitted by the Langevin function, whence the magnetic moment μp = 19256 μB, and the diameter d = 9.6 nm of nanoparticles were determined. Microsized bundle-like particles are superparamagnetic, magnetically guidable and possess high transverse relaxivity of r2 = 397.8 mM−1s−1. Magnetic properties and such high value of transverse relaxivity holds promise for nanobundles application in MRI imaging (MRI contrast agent), as nanobundles may enhance the magnetic field in their surroundings and enhance proton relaxation processes. Our nanobundles can open new opportunities in the biomedical applications, magnetic separation, photonic crystals and magnetic liquid manipulation and can be inspiration for synthesizing novel self-assembled nanoparticle structures. © 2022 Elsevier Ltd and Techna Group S.r.l.
T2  - Ceramics International
T1  - Hierarchical iron oxide nanocomposite: Bundle-like morphology, magnetic properties and potential biomedical application
SP  - Early view
DO  - 10.1016/j.ceramint.2022.02.145
ER  - 

@article{
author = "Tadić, Marin and Lazović, Jelena and Panjan, Matjaž and Kralj, Slavko",
year = "2022",
abstract = "Controlled spatial arrangements of superparamagnetic iron oxide nanoparticles (SPIONs) in complex nanostructures determine fine tuning of physico-chemical properties which, in turn, may lead to new practical applications. We report here on newly observed properties of hierarchical SPIONs nanostructure with bundle-like morphology, also known as nanobundles. Colloidal chemical processes and sol-gel synthesis were used for the synthesis of nanobundles, i.e. i) self-assembly of SPIONs into magnetic nanoparticle clusters, ii) their magnetic assembly to the nanochains, and finally iii) formation of bundle-like hierarchical nanostructure. An XRPD measurements show spinel crystal structure of maghemite/magnetite nanoparticles, EDS analysis reveals Fe, Si and O as main elements whereas SEM/TEM analysis show silica-coated magnetic nanoclusters (∼100 nm) and their hierarchical assemblies with bundle-like morphology of ∼8 μm length and ∼1 μm width. TEM analysis revealed core-shell nature of iron oxide nanoparticle clusters with their size of around 80 nm that were coated by an amorphous silica shell with thickness of ∼15 nm. The nanoclusters in the core are constructed of maghemite/magnetite nanoparticle assembly with primary iron oxide nanoparticle size about 10 nm. The magnetization M data as a function of an applied external magnetic field H were successfully fitted by the Langevin function, whence the magnetic moment μp = 19256 μB, and the diameter d = 9.6 nm of nanoparticles were determined. Microsized bundle-like particles are superparamagnetic, magnetically guidable and possess high transverse relaxivity of r2 = 397.8 mM−1s−1. Magnetic properties and such high value of transverse relaxivity holds promise for nanobundles application in MRI imaging (MRI contrast agent), as nanobundles may enhance the magnetic field in their surroundings and enhance proton relaxation processes. Our nanobundles can open new opportunities in the biomedical applications, magnetic separation, photonic crystals and magnetic liquid manipulation and can be inspiration for synthesizing novel self-assembled nanoparticle structures. © 2022 Elsevier Ltd and Techna Group S.r.l.",
journal = "Ceramics International",
title = "Hierarchical iron oxide nanocomposite: Bundle-like morphology, magnetic properties and potential biomedical application",
pages = "Early view",
doi = "10.1016/j.ceramint.2022.02.145"
}

Tadić, M., Lazović, J., Panjan, M.,& Kralj, S.. (2022). Hierarchical iron oxide nanocomposite: Bundle-like morphology, magnetic properties and potential biomedical application. in Ceramics International, Early view.
https://doi.org/10.1016/j.ceramint.2022.02.145

Tadić M, Lazović J, Panjan M, Kralj S. Hierarchical iron oxide nanocomposite: Bundle-like morphology, magnetic properties and potential biomedical application. in Ceramics International. 2022;:Early view.
doi:10.1016/j.ceramint.2022.02.145 .

Tadić, Marin, Lazović, Jelena, Panjan, Matjaž, Kralj, Slavko, "Hierarchical iron oxide nanocomposite: Bundle-like morphology, magnetic properties and potential biomedical application" in Ceramics International (2022):Early view,
https://doi.org/10.1016/j.ceramint.2022.02.145 . .

TY  - JOUR
AU  - Milin-Lazović, Jelena
AU  - Madžarević, Petar
AU  - Rajović, Nina
AU  - Đorđević, Vladimir
AU  - Milić, Nikola
AU  - Pavlović, Sonja
AU  - Veljković, Nevena V.
AU  - Milić, Nataša M.
AU  - Radenković, Dejan
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9861
AB  - Introduction: The analysis of cell-free DNA (cfDNA) for genetic abnormalities is a promising new approach for the diagnosis and prognosis of pancreatic cancer patients. Insights into the molecular characteristics of pancreatic cancer may provide valuable information, leading to its earlier detection and the development of targeted therapies. Material and Methods: We conducted a systematic review and a meta-analysis of studies that reported cfDNA in pancreatic ductal adenocarcinoma (PDAC). The studies were considered eligible if they included patients with PDAC, if they had blood tests for cfDNA/ctDNA, and if they analyzed the prognostic value of cfDNA/ctDNA for patients’ survival. The studies published before 22 October 2020 were identified through the PubMED, EMBASE, Web of Science and Cochrane Library databases. The assessed outcomes were the overall (OS) and progression-free survival (PFS), expressed as the log hazard ratio (HR) and standard error (SE). The summary of the HR effect size was estimated by pooling the individual trial results using the Review Manager, version 5.3, Cochrane Collaboration. The heterogeneity was assessed using the Cochran Q test and I2 statistic. Results: In total, 48 studies were included in the qualitative review, while 44 were assessed in the quantitative synthesis, with the total number of patients included being 3524. Overall negative impacts of cfDNA and KRAS mutations on OS and PFS in PDAC (HR = 2.42, 95% CI: 1.95–2.99 and HR = 2.46, 95% CI: 2.01–3.00, respectively) were found. The subgroup analysis of the locally advanced and metastatic disease presented similar results (HR = 2.51, 95% CI: 1.90–3.31). In the studies assessing the pre-treatment presence of KRAS, there was a moderate to high degree of heterogeneity (I2 = 87% and I2 = 48%, for OS and PFS, respectively), which was remarkably decreased in the analysis of the studies measuring post-treatment KRAS (I2 = 24% and I2 = 0%, for OS and PFS, respectively). The patients who were KRAS positive before but KRAS negative after treatment had a better prognosis than the persistently KRAS-positive patients (HR = 5.30, 95% CI: 1.02–27.63). Conclusion: The assessment of KRAS mutation by liquid biopsy can be considered as an additional tool for the estimation of the disease course and outcome in PDAC patients.
T2  - Cancers
T1  - Meta-analysis of circulating cell-free dna’s role in the prognosis of pancreatic cancer
VL  - 13
IS  - 14
SP  - 3378
DO  - 10.3390/cancers13143378
ER  - 

@article{
author = "Milin-Lazović, Jelena and Madžarević, Petar and Rajović, Nina and Đorđević, Vladimir and Milić, Nikola and Pavlović, Sonja and Veljković, Nevena V. and Milić, Nataša M. and Radenković, Dejan",
year = "2021",
abstract = "Introduction: The analysis of cell-free DNA (cfDNA) for genetic abnormalities is a promising new approach for the diagnosis and prognosis of pancreatic cancer patients. Insights into the molecular characteristics of pancreatic cancer may provide valuable information, leading to its earlier detection and the development of targeted therapies. Material and Methods: We conducted a systematic review and a meta-analysis of studies that reported cfDNA in pancreatic ductal adenocarcinoma (PDAC). The studies were considered eligible if they included patients with PDAC, if they had blood tests for cfDNA/ctDNA, and if they analyzed the prognostic value of cfDNA/ctDNA for patients’ survival. The studies published before 22 October 2020 were identified through the PubMED, EMBASE, Web of Science and Cochrane Library databases. The assessed outcomes were the overall (OS) and progression-free survival (PFS), expressed as the log hazard ratio (HR) and standard error (SE). The summary of the HR effect size was estimated by pooling the individual trial results using the Review Manager, version 5.3, Cochrane Collaboration. The heterogeneity was assessed using the Cochran Q test and I2 statistic. Results: In total, 48 studies were included in the qualitative review, while 44 were assessed in the quantitative synthesis, with the total number of patients included being 3524. Overall negative impacts of cfDNA and KRAS mutations on OS and PFS in PDAC (HR = 2.42, 95% CI: 1.95–2.99 and HR = 2.46, 95% CI: 2.01–3.00, respectively) were found. The subgroup analysis of the locally advanced and metastatic disease presented similar results (HR = 2.51, 95% CI: 1.90–3.31). In the studies assessing the pre-treatment presence of KRAS, there was a moderate to high degree of heterogeneity (I2 = 87% and I2 = 48%, for OS and PFS, respectively), which was remarkably decreased in the analysis of the studies measuring post-treatment KRAS (I2 = 24% and I2 = 0%, for OS and PFS, respectively). The patients who were KRAS positive before but KRAS negative after treatment had a better prognosis than the persistently KRAS-positive patients (HR = 5.30, 95% CI: 1.02–27.63). Conclusion: The assessment of KRAS mutation by liquid biopsy can be considered as an additional tool for the estimation of the disease course and outcome in PDAC patients.",
journal = "Cancers",
title = "Meta-analysis of circulating cell-free dna’s role in the prognosis of pancreatic cancer",
volume = "13",
number = "14",
pages = "3378",
doi = "10.3390/cancers13143378"
}

Milin-Lazović, J., Madžarević, P., Rajović, N., Đorđević, V., Milić, N., Pavlović, S., Veljković, N. V., Milić, N. M.,& Radenković, D.. (2021). Meta-analysis of circulating cell-free dna’s role in the prognosis of pancreatic cancer. in Cancers, 13(14), 3378.
https://doi.org/10.3390/cancers13143378

Milin-Lazović J, Madžarević P, Rajović N, Đorđević V, Milić N, Pavlović S, Veljković NV, Milić NM, Radenković D. Meta-analysis of circulating cell-free dna’s role in the prognosis of pancreatic cancer. in Cancers. 2021;13(14):3378.
doi:10.3390/cancers13143378 .

Milin-Lazović, Jelena, Madžarević, Petar, Rajović, Nina, Đorđević, Vladimir, Milić, Nikola, Pavlović, Sonja, Veljković, Nevena V., Milić, Nataša M., Radenković, Dejan, "Meta-analysis of circulating cell-free dna’s role in the prognosis of pancreatic cancer" in Cancers, 13, no. 14 (2021):3378,
https://doi.org/10.3390/cancers13143378 . .

TY  - JOUR
AU  - Tadić, Marin
AU  - Panjan, Matjaž
AU  - Vučetić Tadić, Biljana
AU  - Kralj, Slavko
AU  - Lazović, Jelena
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10102
AB  - A porous hematite/alumina nanocomposite is produced by sol-gel combustion synthesis. The XRPD, Raman and FTIR methods show the presence of α-Fe2O3 phase while SEM, TEM, EDS and BET techniques further reveal the formation of porous ellipsoid-like nanostructure of hematite nanoparticles coated by amorphous alumina. Hematite nanoparticles have a size of ~40 nm whereas the porous hematite/alumina nanocomposite particles are ~100 nm in size with characteristic pores of ~7 nm. The M(H) at 300 K exhibits coercivity HC = 293 Oe and magnetization MS = 2.71 emu/g and at 5 K HC = 1150 Oe and MS = 9.25 emu/g. The M(T) under H = 100 Oe shows a bifurcation between ZFC/FC magnetization curves at all measurement temperatures Tirr>350 K (irreversibility temperature) and blocking temperature at TB ~ 305 K. Unexpectedly, the M(T) measurements under H = 10 kOe reveal the suppressed Morin transition at TM = 225 K. The analysis of the results and data from the literature reveal that the porous surface structure of hematite induces the atypical magnetic properties. A magnetic resonance imaging (MRI) properties show the transverse relaxivity rate (r2) of 0.44 mM−1s−1 at 7 T and 1.06 mM−1s−1 at 15.2 T. The investigated nanocomposite particles could be useful in biomedical applications due to their low cytotoxicity and porous nanostructure.
T2  - Ceramics International
T1  - Magnetic properties of mesoporous hematite/alumina nanocomposite and evaluation for biomedical applications
DO  - 10.1016/j.ceramint.2021.12.209
ER  - 

@article{
author = "Tadić, Marin and Panjan, Matjaž and Vučetić Tadić, Biljana and Kralj, Slavko and Lazović, Jelena",
year = "2021",
abstract = "A porous hematite/alumina nanocomposite is produced by sol-gel combustion synthesis. The XRPD, Raman and FTIR methods show the presence of α-Fe2O3 phase while SEM, TEM, EDS and BET techniques further reveal the formation of porous ellipsoid-like nanostructure of hematite nanoparticles coated by amorphous alumina. Hematite nanoparticles have a size of ~40 nm whereas the porous hematite/alumina nanocomposite particles are ~100 nm in size with characteristic pores of ~7 nm. The M(H) at 300 K exhibits coercivity HC = 293 Oe and magnetization MS = 2.71 emu/g and at 5 K HC = 1150 Oe and MS = 9.25 emu/g. The M(T) under H = 100 Oe shows a bifurcation between ZFC/FC magnetization curves at all measurement temperatures Tirr>350 K (irreversibility temperature) and blocking temperature at TB ~ 305 K. Unexpectedly, the M(T) measurements under H = 10 kOe reveal the suppressed Morin transition at TM = 225 K. The analysis of the results and data from the literature reveal that the porous surface structure of hematite induces the atypical magnetic properties. A magnetic resonance imaging (MRI) properties show the transverse relaxivity rate (r2) of 0.44 mM−1s−1 at 7 T and 1.06 mM−1s−1 at 15.2 T. The investigated nanocomposite particles could be useful in biomedical applications due to their low cytotoxicity and porous nanostructure.",
journal = "Ceramics International",
title = "Magnetic properties of mesoporous hematite/alumina nanocomposite and evaluation for biomedical applications",
doi = "10.1016/j.ceramint.2021.12.209"
}

Tadić, M., Panjan, M., Vučetić Tadić, B., Kralj, S.,& Lazović, J.. (2021). Magnetic properties of mesoporous hematite/alumina nanocomposite and evaluation for biomedical applications. in Ceramics International.
https://doi.org/10.1016/j.ceramint.2021.12.209

Tadić M, Panjan M, Vučetić Tadić B, Kralj S, Lazović J. Magnetic properties of mesoporous hematite/alumina nanocomposite and evaluation for biomedical applications. in Ceramics International. 2021;.
doi:10.1016/j.ceramint.2021.12.209 .

Tadić, Marin, Panjan, Matjaž, Vučetić Tadić, Biljana, Kralj, Slavko, Lazović, Jelena, "Magnetic properties of mesoporous hematite/alumina nanocomposite and evaluation for biomedical applications" in Ceramics International (2021),
https://doi.org/10.1016/j.ceramint.2021.12.209 . .